GlassScriptPhysician profile
Sarah Beatty
NPI 1396237566
$1,748.96
in general payments reported to CMS, 2019-2025
29 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $574 · 2022: $281 · 2023: $23.13 · 2024: $467 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $235.20 | 2021-2025 | |
| Novo Nordisk INC | $186.34 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $167.98 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $150.61 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $93.17 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $81.57 | 2021-2022 | |
| Almatica Pharma LLC | $69.30 | 2024-2025 | Loreev Xr |
| Sanofi-Aventis U.S. LLC | $62.66 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $54.91 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.90 | 2024-2025 | Trintellix |
| Alkermes, INC. | $50.69 | 2024-2025 | Aristada, Lybalvi |
| Amarin Pharma, INC. | $49.79 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $49.73 | 2021-2024 | Rexulti |
| Pfizer INC. | $41.30 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.52 | 2024-2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.06 | 2021 | |
| Noven Therapeutics, LLC | $38.48 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $34.77 | 2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $33.01 | 2024-2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $30.78 | 2021 | |
| Neos Therapeutics, LP | $27.96 | 2025 | Adzenys Xr-Odt |
| Eisai INC. | $27.43 | 2021 | |
| Abbott Laboratories | $23.13 | 2023 | Eterna |
| Orexo US, INC. | $23.05 | 2022 | |
| Medtronic, INC. | $18.87 | 2021 | |
| Janssen Scientific Affairs, LLC | $18.50 | 2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $16.63 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.50 | 2024 | |
| Mylan Specialty L.P. | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Beatty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.